MarketScreener Homepage > Equities > Euronext Paris > Sanofi SAN FR0000120578

Report

Real-time Euronext Paris - 04/14 07:06:15 am
84.43	EUR		+0.43%

04/13

C4X DISCOVERY : Up to EUR414 million Exclusive Worldwide Licensing Agreement with Sanofi for C4XD oral IL-17A inhibitor programme

04/13

SWEDISH ORPHAN BIOVITRUM : Sobi Doses First Patient In Phase 3 Trial Of Pediatric Hemophilia Treatment

04/13

SWEDISH ORPHAN BIOVITRUM : First patient dosed in phase 3 XTEND-Kids study with efanesoctocog alfa in children with haemophilia A

Summary

Quotes 5-day view Real-time Quote.

Real-time Euronext Paris

04/08/2021	04/09/2021	04/12/2021	04/13/2021	04/14/2021	Date
84.71(c)	85.06(c)	84.69(c)	84.07(c)	84.43	Last
1 348 869	1 486 808	1 251 699	2 044 073	322 157	Volume
+0.70%	+0.41%	-0.43%	-0.73%	+0.43%	Change

More quotes

Financials

Sales 2021	36 815 M 44 053 M 44 053 M
Net income 2021	5 852 M 7 003 M 7 003 M
Net Debt 2021	7 064 M 8 453 M 8 453 M
P/E ratio 2021	17,9x
Yield 2021	3,90%

Sales 2022	38 935 M 46 590 M 46 590 M
Net income 2022	6 983 M 8 356 M 8 356 M
Net Debt 2022	3 489 M 4 175 M 4 175 M
P/E ratio 2022	15,0x
Yield 2022	4,13%

Capitalization	105 B 125 B 126 B
EV / Sales 2021	3,04x
EV / Sales 2022	2,79x
Nbr of Employees	99 412
Free-Float	88,7%

More Financials

Company

Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (71.2%): prescription drugs in the areas of general medicine (57.3% of net sales; mainly for the treatment of diabetes and cardiovascular diseases) and specialty medicine (42.7%; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune...

Sector

Pharmaceuticals

Calendar

04/28

Earnings Release

More about the company

Notations Surperformance© of Sanofi

Trading Rating :

Investor Rating :

More Ratings

All news about SANOFI

04/13	C4X DISCOVERY : Up to EUR414 million Exclusive Worldwide Licensing Agreement wi..	AQ
04/13	SWEDISH ORPHAN BIOVITRUM : Sobi Doses First Patient In Phase 3 Trial Of Pediatr..	MT
04/13	SWEDISH ORPHAN BIOVITRUM : First patient dosed in phase 3 XTEND-Kids study with..	AQ
04/13	SANOFI : Declares Kiadis Offer Unconditional, All Offer Conditions Now Satisfie..	MT
04/13	SANOFI : Declares Offer for Immunotherapy Company Kiadis Unconditional	MT
04/13	PRESS RELEASE : Evotec launches 'beLAB2122', translating academic innovation fro..	DJ
04/12	French Pharma Firm Sanofi to Build $476 Million Vaccine Production Center in ..	MT
04/12	SANOFI : Buy rating from Goldman Sachs	MD
04/12	SHENZHEN HEPALINK PHARMACEUTICAL : Unit Sells Entire Stake in Kymab Group to Sa..	MT
04/12	SANOFI : to Invest $475 Million for Vaccine Production Site in Singapore	MT
04/12	SANOFI : to create 'cutting-edge' vaccine factory in Singapore	AQ
04/12	C4X DISCOVERY : Signs $492 Million Exclusive Licensing Deal With Sanofi	MT
04/12	SANOFI : Invests $475.5 Million to Build Vaccine Production Site in Singapore	MT
04/12	Sanofi to Invest in Vaccine Production Site in Singapore	DJ
04/12	C4X Discovery Shares Jump on Sanofi Licensing Agreement	DJ

More news

News in other languages on SANOFI

04/13	DGAP-NAV : Effecten-Spiegel AG: Net Asset Value
04/13	LES MARCHÉS EN ACTION : Emission du 13 Avril 2021
04/13	ENGIE, plus forte baisse du CAC 40 à la mi-séance du mardi 13 avril 2021
04/13	SANOFI : plus de 95% de Kiadis détenus à l'issue de l'offre
04/13	BRUSSELS STOCK EXCHANGE : Neutrale start Bel20 voorzien

More news

Analyst Recommendations on SANOFI

04/12	SANOFI : Buy rating from Goldman Sachs	MD
04/08	SANOFI : Buy rating from JP Morgan	MD
04/06	SANOFI : Barclays gives a Neutral rating	MD

More recommendations

Stock Trading Strategies

	SANOFI - 04/12
No turn-around in sight

BUY

More Stock Trading Analysis

Provided by Scoopnest.com

Analysis

As vaccine nationalism deepens, governments pay to bring production home

More Must read

Chart SANOFI

Duration : Period :

Sanofi Technical Analysis Chart | MarketScreener

Full-screen chart

Technical analysis trends SANOFI

	Short Term	Mid-Term	Long Term
Trends	Bullish	Neutral	Neutral

Technical analysis

Income Statement Evolution

More Financials

Consensus

Sell

Buy

Mean consensus	OUTPERFORM
Number of Analysts	26
Average target price	100,61 €
Last Close Price	84,07 €
Spread / Highest target	39,2%
Spread / Average Target	19,7%
Spread / Lowest Target	-16,7%

Consensus

EPS Revisions

More Estimates Revisions

Managers and Directors

Name	Title
Paul Hudson	Chief Executive Officer & Director
Jean-Baptiste Chasseloup de Chatillon	Chief Financial Officer & Executive Vice President
Serge Weinberg	Chairman
John C. Reed	EVP & Global Head-Research & Development
Nestle Frank	Global Head-Immunology Therapeutic Research Area

More about the company

Sector and Competitors

	1st jan.	Capitalization (M$)

SANOFI	6.82%	125 269



JOHNSON & JOHNSON	1.33%	424 524
ROCHE HOLDING AG	-0.95%	286 521
PFIZER INC.	0.43%	204 161
NOVARTIS AG	-4.61%	197 437
MERCK & CO., INC.	-6.56%	193 164

More Results